Lend­ing a hand to a biotech in trou­ble, GSK drops $75M cash to add late-stage an­tibi­ot­ic to port­fo­lio

GSK likes to take pride in be­ing one of the few Big Phar­ma play­ers still ac­tive in an­tibi­otics R&D. And that means keep­ing tabs on what the field has to of­fer.

In a move to beef up the late-stage pipeline, GSK is li­cens­ing a late-stage an­tibi­ot­ic can­di­date from Spero Ther­a­peu­tics. In do­ing so, it’s com­ing to the res­cue of a strug­gling biotech that’s crum­bled in the wake of an FDA re­jec­tion and raised doubts about its abil­i­ty to car­ry on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER